PGEN
Precigen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.10
−0.56%Aug 29, 2026, 01:45 UTC
Jeffrey B. Kindler, a director at Precigen, Inc., sold 185,000 shares of the company's common stock on August 26, 2026, for a total value of $1,376,400.
Source:Aug 25, 2026, 11:00 UTC
Precigen Inc. reported second-quarter net product revenue of $53.1 million for PAPZIMEOS, more than double the prior quarter, and achieved quarterly profitability.
Source:Aug 4, 2026, 20:01 UTC
Precigen reported second quarter 2026 financial results, with PAPZIMEOS net revenue of $53.1 million and quarterly profitability, and cash totaling $38.7 million as of June 30, 2026.
Jun 24, 2026, 00:00 UTC
Precigen, Inc. elected Randal Kirk, Nancy Howell Agee, Cesar Alvarez, Steven Frank, and Vinita Gupta as directors on June 18, 2026.
Jun 15, 2026, 10:40 UTC
Precigen Inc. was granted orphan drug exclusivity by the FDA for PAPZIMEOS, its treatment for recurrent respiratory papillomatosis.